1. Yousefsani BS, Ghobadi A, Dadmehr M and Shirani K. Castor Oil. A natural remedy with promising potential for Parkinson 's disease prevention. Jundishapur. J. Nat. Pharm. Prod. 2024; 19(1): e143882. [
DOI:10.5812/jjnpp-143882]
2. Santiago JA and Potashkin JA. Physical activity and lifestyle modifications in the treatment of neurodegenerative diseases. Front. Aging. Neurosci. 2023; 15: 1185671. [
DOI:10.3389/fnagi.2023.1185671]
3. Xu L and Pu J. Alpha-Synuclein in Parkinson 's disease: from Pathogenetic dysfunction to potential clinical Application. Parkinsons. Dis. 2016; 2016: 1720621. [
DOI:10.1155/2016/1720621]
4. Váradi C. Clinical features of Parkinson 's disease. The evolution of critical symptoms. Biology (Basel). 2020; 9(5): 103. [
DOI:10.3390/biology9050103]
5. Radad K, Moldzio R, Krewenka C, Kranner B and Rausch W-D. Pathophysiology of non-motor signs in Parkinson 's disease: some recent uparkinson ating with brief presentation. Explor. Neuroprot. Ther. 2023; 3: 24-46. [
DOI:10.37349/ent.2023.00036]
6. Gouda NA, Elkamhawy A and Cho J. Emerging Therapeutic strategies for Parkinson 's disease and future prospects: A 2021 update. Biomedicines 2022; 10(2): 371. [
DOI:10.3390/biomedicines10020371]
7. Shirani K, Hassani FV, Azar-Khiavi KR, Samie Moghaddam Z and Karimi GhR. Determination of methanol in Iranian herbal distillates. J. Complement. Integr. Med. 2016; 13(2): 123-7. [
DOI:10.1515/jcim-2015-0041]
8. Shang A, Cao SY, Xu XY, Gan R-Y, Tang G-Y, Corke H, Mavumengwana V and Li H-B. Bioactive compounds and biological functions of Garlic (Allium sativum L.). Foods 2019; 8(7): 246. [
DOI:10.3390/foods8070246]
9. Petrovska BB and Cekovska S. Extracts from the history and medical properties of Garlic. Pharmacogn. Rev. 2010; 4(7): 106-10. [
DOI:10.4103/0973-7847.65321]
10. Verma T, Aggarwal A, Dey P, Chauhan AK, Rashid S, Chen K-T and Sharma R. Medicinal and therapeutic properties of garlic, garlic essential oil, and garlic-based snack food: An updated review. Front. Nutr. 2023; 10. [
DOI:10.3389/fnut.2023.1120377]
11. Bigham M, Mohammadipour A, Hosseini M, Malvandi AM, Ebrahimzadeh-Bideskan A. Neuroprotective effects of garlic extract on dopaminergic neurons of substantia nigra in a rat model of Parkinson 's disease: motor and non-motor outcomes. Metab. Brain. Dis. 2021; 36(5): 927-937. [
DOI:10.1007/s11011-021-00705-8]
12. Alavi Shirazi A, Mohammad Hadi SMH and Esfahani MM. Makhz al-Adawieh. Tehran, Iran: Iran University of Medical Sciences. Institute of Medical History Studies. Islamic and complementary medicine. 1387, P. 288. [Persian].
13. Mohammadzadeh L, Hosseinzadeh H, Abnous K and Razavi BM. Neuroprotective potential of crocin against Mal-induced motor deficit and neurochemical alterations in rats. Environ. Sci. Pollut. Res. Int. 2018; 25(5): 4904-4914. [
DOI:10.1007/s11356-017-0842-0]
14. Kraeuter A-K, Guest PC and Sarnyai Z. The open field test for measuring locomotor activity and anxiety-like behavior. Methods Mol. Biol. 2019; 1916: 99-103. [
DOI:10.1007/978-1-4939-8994-2_9]
15. Costall B and Naylor RJ. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia. 1974; 34(3): 233-41. [
DOI:10.1007/BF00421964]
16. Yousefsani BS, Bahrami B, Qobadi A, et al. The selective cytotoxicity of the hydroalcoholic extract of Santalum Album Linn wood on A375 and SK-MEL-3 human malignant Melanoma cells: Iran. J. Pharmaceutical. Sci. 2022; 18(2).
17. Yousefsani BS, Salimi A, Imani F, Ramezani M, Shirani K, Seydi E and Pourahmad J. Risperidone toxicity on human blood lymphocytes in nano molar concentrations. Drug. Res. 2022; 72(6): 343-349. [
DOI:10.1055/a-1830-8701]
18. Shirani K, Iranshahi M, Askari VR, Gholizadeh Z, Attaran Zadeh A, Zeinali M and Vahdati Hassani F. Comparative evaluation of the protective effects of oral administration of auraptene and umbelliprenin against CFA-induced chronic inflammation with polyarthritis in rats. Biomed. Pharmacother. 2021; 139: 111635. [
DOI:10.1016/j.biopha.2021.111635]
19. Nikkhah E, Shirani K, Rezaee R and Karimi GhR. Protective effects of taurine against hepatotoxicity induced by pharmaceuticals and environmental chemicals. Toxicol. Environ. Chem. 2021; 103(1): 56-84. [
DOI:10.1080/02772248.2021.1892113]
20. Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, Skaper SD and Giusti P. Generation of a α-synuclein-based rat model of Parkinson 's disease. Neurobiol. Dis. 2008; 30(1): 8-18. [
DOI:10.1016/j.nbd.2007.11.002]
21. Sedelis M, Schwarting RK and Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinson 's disease. Behav. Brain. Res. 2001; 125(1-2): 109-25. [
DOI:10.1016/S0166-4328(01)00309-6]
22. Prasad EM and Hung S-Y. Behavioral tests in Neurotoxin-Induced animal models of Parkinson's disease. Antioxidants (Basel). 2020; 16; 9(10): 1007. [
DOI:10.3390/antiox9101007]
23. Duty S and Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 2011; 164(4): 1357-91. [
DOI:10.1111/j.1476-5381.2011.01426.x]
24. Tartaglione AM, Venerosi A and Calamandrei G. Early-life toxic insults and onset of sporadic neurodegenerative diseases-an overview of experimental studies. Curr. Top. Behav. Neurosci. 2016; 29: 231-264. [
DOI:10.1007/7854_2015_416]
25. Jamshidi AH, Eghbalian F, Mahroozade S, Mohammadi Kenari H, Ghobadi A and Yousefsani BS. Recommended natural products in Alzheimer's disease based on traditional Persian medicine. J. Med. Plants 2020; 19(75): 17-29. [
DOI:10.29252/jmp.19.75.17]
26. Nagatsu T and Sawada M. L-dopa therapy for Parkinson 's disease: past, present, and future. Parkinsonism. Relat. Disord. 2009; 15(Supp. 1): S3-8. [
DOI:10.1016/S1353-8020(09)70004-5]
27. Kamranfar F, Jaktaji RP, Shirani K, Jamshidi AH, Samiei F, Arjmand A, Khoramjouy M, Faizi M, Pourahmad J. Protective effect of a standardized Allium jesdianum extract in an Alzheimer's disease induced rat model. Neurosci. Lett. 2023; 815: 137491. [
DOI:10.1016/j.neulet.2023.137491]
28. Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM and Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr. Neuropharmacol. 2013; 11(3): 315-35.
29. Nakamagoe K, Watanabe M, Takeda T, Mizutani T and Tamaoka A. Parkinsonism with organophosphate poisoning. BMJ Case Rep. 2009; 2009: bcr0420091766. [
DOI:10.1136/bcr.04.2009.1766]
30. Dias V, Junn E and Mouradian MM. The role of oxidative stress in Parkinson 's disease. J. Parkinsons. Dis. 2013; 3(4): 461-91. [
DOI:10.3233/JPD-130230]
31. Chakraborty S, Bornhorst J, Nguyen TT and Aschner M. Oxidative stress mechanisms underlying Parkinson 's disease-associated neurodegeneration in C. elegans. Int. J. Mol. Sci. 2013; 14(11): 23103-28. [
DOI:10.3390/ijms141123103]
32. Liu H, Mao P, Wang J, Wang T, Xie C-H. Allicin protects PC12 cells against 6-OHDA-induced oxidative stress and Mitochondrial dysfunction via regulating Mitochondrial dynamics. Cell. Physiol. Biochem. 2015; 36: 966-979. [
DOI:10.1159/000430271]
33. Rojas P, Serrano-García N, Medina-Campos ON, Pedraza-Chaverri J, Maldonado PD and Ruiz-Sánchez E. S-Allylcysteine, a garlic compound, protects against oxidative stress in 1-methyl-4-phenylpyridinium-induced parkinson ism in mice. J. Nutr. Biochem. 2011; 22(10): 937-944. [
DOI:10.1016/j.jnutbio.2010.08.005]
34. Khovarnagh N and Seyedalipour B. Antioxidant, histopathological and biochemical outcomes of short-term exposure to acetamiprid in liver and brain of rat: The protective role of N-acetylcysteine and S-methylcysteine. Saudi. Pharm. J. 2021; 29(3): 280-289. [
DOI:10.1016/j.jsps.2021.02.004]
35. Shao F, Wang X, Wu H, Wu Q and Zhang J. Microglia and neuroinflammation: Crucial pathological mechanisms in traumatic brain Injury-Induced neurodegeneration. Front. Aging Neurosci. 2022; 14: 825086. [
DOI:10.3389/fnagi.2022.825086]
36. Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int. Immunol. 2021; 33(3): 127-148. [
DOI:10.1093/intimm/dxaa078]
37. Ban JO, Oh JH, Kim TM, Kim Dj, Jeong H-S, Han SB and Hong JT. Anti-inflammatory and arthritic effects of thiacremonone, a novel sulfur compound isolated from garlic via inhibition of NF-kappaB. Arthritis. Res. Ther. 2009; 11(5): R145. [
DOI:10.1186/ar2819]
38. Lin G, Lee Y-J, Choi D-Y, Han SB, Jung JK, Hwang BY, Moon DC, Kim Y, Lee MK, Oh K-W, Jeong HS, Leem JY, Shin HK, Lee JH and Hong JT. Anti-amyloidogenic effect of thiacremonone through anti-inflamation in vitro and in vivo models. J. Alzheimers. Dis. 2012; 29(3): 659-676. [
DOI:10.3233/JAD-2012-111709]